Skip to main content

Immune Checkpoint Inhibitors In Cancer

In Order to Read Online or Download Immune Checkpoint Inhibitors In Cancer Full eBooks in PDF, EPUB, Tuebl and Mobi you need to create a Free account. Get any books you like and read everywhere you want. Fast Download Speed ~ Commercial & Ad Free. We cannot guarantee that every book is in the library!

Immune Checkpoint Inhibitors in Cancer

Immune Checkpoint Inhibitors in Cancer Book
Author : Fumito Ito,Marc Ernstoff
Publisher : Elsevier Health Sciences
Release : 2018-09-03
ISBN : 0323549500
Language : En, Es, Fr & De

GET BOOK

Book Description :

Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on immune checkpoint inhibitors and presents this information in a compact, easy-to-digest resource. It’s an ideal concise reference for trainee and practicing medical oncologists, as well as those in research. Discusses the current understanding of how to best harness the immune system against different types of cancer at various stages. Helps you translate current research and literature into practical information for daily practice. Presents information logically organized by disease site. Covers tumor immunology and biology; toxicities associated with immune checkpoint inhibitors; and future outlooks. Consolidates today’s available information on this timely topic into one convenient resource.

Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors

Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors Book
Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,National Cancer Policy Forum
Publisher : National Academies Press
Release : 2019-09-05
ISBN : 0309490898
Language : En, Es, Fr & De

GET BOOK

Book Description :

In recent years, significant progress has been made in the clinical development and use of various types of cancer immunotherapy, all of which rely on the immune system to fight cancer. The majority of new cancer drug applications submitted to the Food and Drug Administration (FDA) are for immunotherapies or combinations involving immunotherapies. One type of immunotherapy is an immune checkpoint inhibitor. Cells in the human body have proteins that regulate the immune system response to foreign invaders (e.g., cancer cells, microorganisms). However, cancer cells can coopt these "checkpoint" proteins and thwart the immune system's ability to recognize and attack cancer cells. To help promote an immune response to cancer, researchers have developed immune checkpoint inhibitors that enable T-cells to recognize cancer cells as foreign and to prevent deactivation of an immune system response. To examine the challenges and opportunities to develop combination cancer therapies that include immune checkpoint inhibitors, the National Cancer Policy Forum held a workshop on July 16â€"17, 2018, in Washington, DC. This workshop convened stakeholders with a broad range of expertise, including cancer researchers, clinicians, patient advocates, and representatives from industry, academia, and government. This publication summarizes the presentations and discussions from the workshop.

Fast Facts Immuno Oncology

Fast Facts  Immuno Oncology Book
Author : Stephen Clarke,Bob T. Li
Publisher : Karger Medical and Scientific Publishers
Release : 2021-07-07
ISBN : 3318068217
Language : En, Es, Fr & De

GET BOOK

Book Description :

The treatment of cancer has been revolutionized by therapies that modulate the immune system, with benefits for quality of life and survival. Standards of care have changed to reflect developments, but the area is moving fast. Keeping abreast of new therapies and trial data can be challenging. This second edition of 'Fast Facts: Immuno-Oncology' takes you from the fundamentals of immunology through to the new concepts of immunoediting and immunotherapy and likely future directions. Whether you have worked in oncology for decades and need a refresher or you are just starting out and need a crash course, this book provides all you need to know about immuno-oncology, concisely summarized. Table of Contents: • Components of the immune system • How cancers evade the immune system • How cancer immunotherapy works • Clinical use of immune checkpoint inhibitors • The future of immuno-oncology

06 UNCOMMON AND POTENTIALLY LIFE THREATENING COMPLICATIONS FROM THE IMMUNE CHECKPOINT INHIBITOR NIVOLUMAB AT AN ONCO HOSPITALIST INPATIENT SERVICE

06   UNCOMMON AND POTENTIALLY LIFE THREATENING COMPLICATIONS FROM THE IMMUNE CHECKPOINT INHIBITOR NIVOLUMAB AT AN ONCO HOSPITALIST INPATIENT SERVICE Book
Author : Pramod Gaudel
Publisher : Unknown
Release : 2017
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Introduction: Immune checkpoint inhibition augments the immunologic reaction against tumor cells in several cancer types, with improved survival in various malignancies, but increased autoimmunity as side effects[1-3]. These conditions are collectively called immune-related adverse events (irAEs)[3]. Methods: We report on selected uncommon high-grade potentially life-threatening toxicities encountered in three patients with metastatic squamous cell carcinoma of the lungs who received the anti-PD-1 agent nivolumab. Results: Case #1: 76 years-old man who developed edema with elevated troponin T, NT-ProBNP, and an AV block one week after his third dose of nivolumab. His workup was consistent with myocarditis, treated with high doses of corticosteroids, plasmapheresis, infliximab (anti-TNF-alpha), and rituximab (anti-CD20) to further suppress both T and B cells. Case # 2: 66 years-old woman who developed progressive symmetric lower extremities weakness and hyporeflexia nine days after her second dose of nivolumab. She developed a Guillain-Barre like syndrome, acute inflammatory demyelinating polyradiculoneuropathy (AIDP) variant, and received five doses of IVIG with excellent results. Case # 3: 69 years-old man with progressive muscle weakness, dysphagia, ptosis and difficulties holding his head up one week after his third dose of nivolumab. He had myositis and myasthenia gravis, which were successfully treated with high doses of corticosteroids and five doses of IVIG. Conclusions: Although rare, fulminant and fatal toxic effects may present with immune checkpoint inhibition. Immune-mediated myocarditis is a rare and often fatal irAE of immune checkpoint inhibitory therapy[4]. The incidence of immune-mediated myocarditis is thought to be 0.06% for single agent nivolumab and 0.27% for combination nivolumab/ipilimumab. Combination checkpoint blockade is associated with both a higher incidence and severity of immune-mediated myocarditis[5]. The true incidence of immune-mediated myocarditis may be underestimated as this condition has a variable clinical presentation, with symptomatology ranging from subclinical disease to chest pain, edema, cardiac failure, cardiogenic shock, arrhythmias, and sudden death[4,5]. Although neurological irAEs are considered rare in comparison with hepatitis, colitis, pneumonitis, and endocrinopathies, one emerging side effect is myasthenia gravis (MG), alone or in combination with other toxicities[6,7]. Nivolumab-related MG (nivoMG) should be highly suspected in patients who develop ptosis, diplopia, and general weakness[8]. Bulbar symptoms and myasthenic crisis have been observed more frequently in nivoMG than idiopathic MG[9]. Nivolumab-induced inflammatory demyelinating polyradiculopathy mimicking Guillain-Barre syndrome seemsu200b to be rarer, with severe few cases reported in the literature[10-13]. Guillain-Barre like syndrome should be suspected when progressive weakness and areflexia occur anytime after treatment with immune checkpoint inhibitors. Knowledge about these conditions expedites the ability of the practitioner to properly manage them, therefore ensuring the best possible outcomes. Some high-grade irAEs with nivolumab are managed with corticosteroids and other immune modulating agents.Referencest1.tKorman AJ, Peggs KS, Allison JP: Checkpoint blockade in cancer immunotherapy. Advances in immunology 90:297-339, 2006t2.tPardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer 12:252-264, 2012t3.tTopalian SL, Drake CG, Pardoll DM: Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer cell 27:450-461, 2015t4.tTay RY, Blackley E, McLean C, et al: Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. British journal of cancer 117:921, 2017t5.tJohnson DB, Balko JM, Compton ML, et al: Fulminant myocarditis with combination immune checkpoint blockade. New England Journal of Medicine 375:1749-1755, 2016t6.tMakarious D, Horwood K, Coward J: Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. European Journal of Cancer 82:128-136, 2017t7.tKimura T, Fukushima S, Miyashita A, et al: Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer science 107:1055-1058, 2016t8.tChen Y-H, Liu F-C, Hsu C-H, et al: Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: case report. Medicine 96, 2017t9.tSuzuki S, Ishikawa N, Konoeda F, et al: Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89:1127-1134, 2017t10.tSupakornnumporn S, Katirji B: Guillainu2013Barre syndrome triggered by immune checkpoint inhibitors: a case report and literature review. Journal of clinical neuromuscular disease 19:80-83, 2017t11.tTanaka R, Maruyama H, Tomidokoro Y, et al: Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillainu2013Barru00e9 syndrome: a case report. Japanese journal of clinical oncology 46:875-878, 2016t12.tJacob A, Unnikrishnan DC, Mathew A, et al: A case of fatal Guillain-Barre syndrome from anti-PD1 monoclonal antibody use. Journal of Cancer Research Clinical Oncology 142:1869, 2016t13.tFukumoto Y, Kuwahara M, Kawai S, et al: Acute demyelinating polyneuropathy induced by nivolumab. J Neurol Neurosurg Psychiatry 89:435-437, 2018Keywordsanti-PD-1, nivolumab, high-grade immune-related adverse event, onco-hospitalist.

SITC s Guide to Managing Immunotherapy Toxicity

SITC   s Guide to Managing Immunotherapy Toxicity Book
Author : Marc S. Ernstoff, MD,Igor Puzanov, MD, MSCI, FACP,Caroline Robert, MD, PhD,Adi M. Diab, MD,Peter M. Hersey, MD, PhD
Publisher : Springer Publishing Company
Release : 2019-03-15
ISBN : 0826172156
Language : En, Es, Fr & De

GET BOOK

Book Description :

The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers. With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care. Key Features: Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy Provides numerous tables that condense and highlight pertinent information for quick reference Describes the various clinical presentations and toxic reactions caused by immunotherapy Purchase includes access to the eBook for use on most mobile devices or computer

Immune Checkpoint Molecules and Cancer Immunotherapy

Immune Checkpoint Molecules and Cancer Immunotherapy Book
Author : Alexandr V. Bazhin,Amedeo Amedei,Svetlana Karakhanova
Publisher : Frontiers Media SA
Release : 2019-01-22
ISBN : 288945732X
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Immune Checkpoint Molecules and Cancer Immunotherapy book written by Alexandr V. Bazhin,Amedeo Amedei,Svetlana Karakhanova, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Fast Facts Immuno Oncology

Fast Facts  Immuno Oncology Book
Author : S. Clarke,B.T. Li
Publisher : Karger Medical and Scientific Publishers
Release : 2021-06-29
ISBN : 3318068225
Language : En, Es, Fr & De

GET BOOK

Book Description :

The treatment of cancer has been revolutionized by therapies that modulate the immune system, with benefits for quality of life and survival. Standards of care have changed to reflect developments, but the area is moving fast. Keeping abreast of new therapies and trial data can be challenging. This second edition of 'Fast Facts: Immuno-Oncology' takes you from the fundamentals of immunology through to the new concepts of immunoediting and immunotherapy and likely future directions. Whether you have worked in oncology for decades and need a refresher or you are just starting out and need a crash course, this book provides all you need to know about immuno-oncology, concisely summarized. Table of Contents: • Components of the immune system • How cancers evade the immune system • How cancer immunotherapy works • Clinical use of immune checkpoint inhibitors • The future of immuno-oncology

Immunotherapy

Immunotherapy Book
Author : Aung Naing,Joud Hajjar
Publisher : Springer Nature
Release : 2020-04-16
ISBN : 3030410080
Language : En, Es, Fr & De

GET BOOK

Book Description :

Immunotherapy is a rapidly evolving field that mandates frequent revision of the book as new insights to fight cancer emerge. The third edition of Immunotherapy is an updated overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. It explores the breath of immunotherapeutic strategies available to treat a wide range of cancers, from melanoma and non-small cell lung cancer to gastrointestinal, genitourinary, gynecologic and nervous system malignancies. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the challenges associated with their use undoubtedly increase. As objective response is limited to a subset of patients and is often associated with distinct immune related side effects that are potentially life threatening, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. In the absence of a validated predictive biomarker, innovative technologies and assays are being used to identify critical biomarkers that drive the immune response. Hence, a chapter to provide a basic understanding of the diagnostic procedures has been included besides the chapter on the cellular components of the human immune system. This new edition will also inform readers on use of novel microbiome and imaging approaches. Finally, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies as the authors recognize the importance of including missing patient voice in clinical trials and longitudinal assessment of symptom reports. In short, the third edition of this book provides a comprehensive overview of the latest developments in the field of immune-oncology that will help health care professionals make informed treatment decisions. The book’s chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.

Advances in Immuno oncology

Advances in Immuno oncology Book
Author : Mark A. Socinski
Publisher : Unknown
Release : 2015
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Advances in Immuno oncology book written by Mark A. Socinski, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy

Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy Book
Author : Maria E. Suarez-Almazor,Leonard H. Calabrese
Publisher : Springer Nature
Release : 2021-02-16
ISBN : 3030568245
Language : En, Es, Fr & De

GET BOOK

Book Description :

With the increasing use of immune checkpoint inhibitors (ICI) across various cancers, the trends for indication at earlier stages, and the use of combination immunotherapy, the frequency of ICI-induced immune-related adverse events (irAE) is expected to grow substantially. Management of these irAE is challenging as it requires not only consideration of the toxicity but also risk-benefit ratios with respect to the primary cancer. Several rheumatic irAE have been reported with ICI therapy including arthritis, myositis, polymyalgia-like syndromes, sicca/Sjogren-like manifestations, and several other less common systemic autoimmune features commonly associated with connective tissue disease. This handbook provides clinicians with a comprehensive overview of the management of rheumatic irAE that develop from cancer immunotherapy. It focuses on the irAE seen with ICI, the most frequently used agents in treating cancer. It provides an overview of cancer immunology, immunotoxicity, and immunotherapies such as ICI, cytokine-based therapy, and CART. It examines the epidemiology, clinical manifestations, diagnosis, differential diagnosis, and treatment of a variety of rheumatic immune-related adverse events arising from these therapies. Chapters also cover cancer immunotherapy in patients with preexisting rheumatic diseases such as inflammatory arthritis and other connective tissue disorders. The book helps clinicians to distinguish the current types of cancer immunotherapy and general toxicity patterns, recognize and diagnose rheumatic clinical syndromes, understand the pathogenesis of irAE, and consider risk–benefit ratios when managing patients with rheumatic irAE. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy is an essential resource for physicians and related professionals, residents, fellows, graduate students and nurses alike in rheumatology, clinical immunology, oncology, and internal medicine.

Exploring the Effect of Chronic Inflammation on Response to Immune Checkpoint Inhibitors in Cancer

Exploring the Effect of Chronic Inflammation on Response to Immune Checkpoint Inhibitors in Cancer Book
Author : Sherif Mohamed El-Refai
Publisher : Unknown
Release : 2017
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Exploring the Effect of Chronic Inflammation on Response to Immune Checkpoint Inhibitors in Cancer book written by Sherif Mohamed El-Refai, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

The Basics of Cancer Immunotherapy

The Basics of Cancer Immunotherapy Book
Author : Haidong Dong,Svetomir N. Markovic
Publisher : Springer
Release : 2018-01-05
ISBN : 3319706225
Language : En, Es, Fr & De

GET BOOK

Book Description :

This book provides patients and their physicians (especially “non-oncologist” health care providers) with a clear and concise introduction to cancer immunotherapy, which, unlike traditional forms of cancer therapy, acts by boosting the patient’s own immune system to fight cancer. The unique features of cancer immunotherapy make its management, monitoring and side-effects different from those of traditional cancer therapy. Especially novel are the side effects of cancer immunotherapy, necessitating greater awareness for both patients and physicians in order to minimize complications of therapy. The patient-friendly, concise, easy-to-understand, and up-to-date knowledge presented in this book will inform patients about the benefits and risks of cancer immunotherapy, and help them and their care providers to understand how immunotherapy would control their unique disease. Researchers and academic professionals in the field of cancer immunotherapy will also find clear and useful information to help them communicate with patients or address unresolved problems. Some key features of the book are: Expertise. All editors and authors are scientists and oncologists specializing in cancer immunotherapy, and are involved in scientific discovery from the early stage of immune-checkpoint inhibitors to today’s daily patient care. Their insights, expertise and experience guarantee the high quality and authority in the science, medicine and practice of cancer immunotherapy. Patient-friendly. This book is written for cancer patients in order to meet their needs when considering immunotherapy. As an educational tool, this book will help the reader balance the risks and benefits based on both science and clinical facts, and therefore to make the best choice in receiving or withdrawing from immunotherapy. Disease Specificity. Cancer is a complicated disease involving multiple stages and pathology. Its response to immunotherapy is individualized and varies depending on cancer types. The authors’ expertise in treating different types of cancers, including melanoma, lung, kidney, bladder, and lymphoma, provides disease-specific insights in applying immunotherapy to each disease.

Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors Book
Author : Medtech Ventures
Publisher : Unknown
Release : 2020-01-18
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Global immune checkpoint inhibitors market reached $22 billion in 2019, quite a growth giving the fact that the first product in this new class of therapeutics was launched just 9 years ago and the market was valued at $360 million in 2011. The market took off in 2015, the first full year on the market of Keytruda and Opdivo, the two PD-1 inhibitors from Merck and Bristol-Myers Squibb, respectively. US is the largest market, accounting for 62% of global revenue, the country has the highest penetration and the largest number of active users, which was estimated at 300,000 patients in 2019. Europe is a distant second with 18%, with Germany it's largest market. Japan currently accounts for 9% of the global market and China for 4%. However, China has a local industry that has managed to launch four PD-1 monoclonal antibody checkpoint inhibitors in 2019. Immune checkpoint inhibitors are tumor agnostic and represent some of the most advanced treatments available to patients with cancer. Their introduction has improved outcomes for patients with a wide range of solid tumors including: skin, lung, liver, kidney, stomach, breast, bladder, colon, head & neck, liver and cervical cancers. Immune checkpoint inhibitors are rapidly becoming the primary first-line treatments for patients with metastatic non-small cell lung cancer, metastatic melanoma and metastatic renal cell carcinoma. The movement to first-line treatment has occurred quickly, driven by significantly better outcomes in selected patients. There are currently over 3,000 clinical trials actively exploring the utility of new and existing checkpoint inhibitors in over 20 types of cancers, both as monotherapy and in combination with other cancer therapeutics. Despite accumulating evidence suggesting that only a fraction of cancer patients benefit from checkpoint inhibiting therapies, severe immune-related adverse events, and the need for predictive biomarkers, experts forecast the market to reach $40 billion by 2025. Immune Checkpoint Inhibitors - Technology and Market Forecast report offers a helicopter snapshot of current situation in this fast evolving dynamic market. The report is an insightful document targeted at senior executives in the pharmaceutical and biopharmaceutical industries. Strategists, brand, product, innovation, research, portfolio managers as well as venture capital professionals will find this report of particular value.

Regulation of Cancer Immune Checkpoints

Regulation of Cancer Immune Checkpoints Book
Author : Jie Xu
Publisher : Springer Nature
Release : 2020-03-17
ISBN : 9811532664
Language : En, Es, Fr & De

GET BOOK

Book Description :

This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers have been completely resistant to the therapy. The potentially lethal adverse effects of checkpoint blockade represent another major challenge, the mechanisms of which remain poorly understood. Compared to the cancer signaling pathways, such as p53 and Ras, mechanistic studies on immune checkpoint pathways are still in their infancy. To improve the responses to checkpoint blockade therapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune checkpoint therapy and its challenges, and subsequently describes the regulation of checkpoints at different levels. In closing, it discusses recent therapeutic developments based on mechanistic findings, and outlines goals for future translational studies. The book offers a valuable resource for researchers in the cancer immunotherapy field, helping to form a roadmap for checkpoint regulation and develop safer and more effective immunotherapies.

Combinatorial Approaches to Enhance Anti Tumor Immunity Focus on Immune Checkpoint Blockade Therapy

Combinatorial Approaches to Enhance Anti Tumor Immunity  Focus on Immune Checkpoint Blockade Therapy Book
Author : Patrik Andersson,Christian Ostheimer
Publisher : Frontiers Media SA
Release : 2019-12-27
ISBN : 2889631613
Language : En, Es, Fr & De

GET BOOK

Book Description :

The immune system harbors great potential for controlling and eliminating tumors. Recent developments in the field of immuno-oncology has led to unprecedented clinical benefits for a broad spectrum of solid tumors. However, immunotherapy (IT) approaches currently have several limitations including (i) low response rate; (ii) development of resistance and (iii) causing severe immune-related adverse effects (IrAEs), which underline the importance of adequate patient selection. Importantly, IT holds promising synergistic potential when combined with standard-of-care chemotherapy, radiotherapy (RT) and anti-angiogenic therapy (AAT) as part of multi-modal oncologic treatment regimes. Published data suggest that there are potential synergy between RT and AAT, which ultimately could help potentiate the response to IT. However, the complex interactions between RT and IT and/or AAT remain poorly understood. Many research questions including optimal timing, scheduling and dosing, as well as patient selection and side effects of combined therapy approaches, remain to be addressed. This Research Topic aims to give a comprehensive overview of the current field with particular emphasis on the future outlook of RT and AAT as complementary approaches to improve IT in solid tumors.

Novel Immunotherapeutic Approaches to the Treatment of Cancer

Novel Immunotherapeutic Approaches to the Treatment of Cancer Book
Author : Paul D. Rennert
Publisher : Springer
Release : 2016-05-30
ISBN : 3319298275
Language : En, Es, Fr & De

GET BOOK

Book Description :

Cancer care is undergoing a radical transformation as novel technologies are directed toward new treatments and personalized medicine. The most dramatic advances in the treatment of cancer have come from therapeutics that augment the immune response to tumors. The immune checkpoint inhibitors are the best-known and most highly advanced examples of Immune Therapeutics targeting tumor cells and include approved antibody drugs directed at the cell surface proteins CTLA4 and PD-1. These are now considered foundational treatments for several solid tumor indications, and that list of indications is growing quickly. More broadly, antibodies have become workhorse molecules across the entire immunotherapy landscape. Antibodies to novel targets modulate the activity of diverse immune cell regulatory proteins. Engineered antibodies can induce tumor cell death or expose tumor cells to poisonous toxins (ADCC and ADC, respectively). Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating remarkable tumor-specific cellular therapeutics (CAR-T, CAR-NK). Beyond antibody-based therapies there are highly diverse and differentiated technology tool kits being applied to immunotherapy. Small molecule drugs are being developed to attack the tumor microenvironment, novel tumor vaccine approaches are showing great promise, patient lymphocytes are being isolated, expanded and reintroduced to patients, gene-editing techniques are becoming widely deployed, and a vast number of new tumor targets, and mutated tumor proteins (neoantigens), are being discovered. The past decade has seen unprecedented success in the treatment of diverse cancers. The authors of this volume have been asked to not only review progress to date, but importantly, to look ahead, and anticipate the evolution of cancer treatment across diverse Immune Therapeutic approaches. Our hypothesis is that the advances we are seeing across the immunotherapy landscape will further evolve and synergize, leading us finally to outright cures for many cancers.

Fast Facts Managing immune related Adverse Events in Oncology

Fast Facts  Managing immune related Adverse Events in Oncology Book
Author : Bernardo L. Rapoport,Helen Westman
Publisher : Karger Medical and Scientific Publishers
Release : 2019-06-17
ISBN : 1912776391
Language : En, Es, Fr & De

GET BOOK

Book Description :

Immunotherapeutic products, and immune checkpoints inhibitors in particular, are increasingly used in the management of malignancies, both as monotherapies and in combination. Adverse events tend to be mild to moderate, but they can be severe or even life-threatening. Prompt recognition and effective management are vital. 'Fast Facts: Managing Immune-Related Adverse Events' is an accessible overview that brings together clear explanations and management summaries. This highly readable handbook examines the possible effects of immunotherapies on the skin, gastrointestinal tract, liver, endocrine system and lungs, as well as less frequent reactions. Detailed descriptions and evidence-based guidance for practical application make 'Fast Facts: Managing Immunotherapy-Related Adverse Events' an invaluable resource for all healthcare professionals who may encounter patients using immunotherapy, including nurses, who are particularly well placed to identify changes linked to use of immunotherapy, those working in the emergency department and primary care providers.

Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors

Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors Book
Author : Engineering National Academies of Sciences (and Medicine)
Publisher : Unknown
Release : 2019
ISBN : 9780309490870
Language : En, Es, Fr & De

GET BOOK

Book Description :

"In recent years, significant progress has been made in the clinical development and use of various types of cancer immunotherapy, all of which rely on the immune system to fight cancer. The majority of new cancer drug applications submitted to the Food and Drug Administration (FDA) are for immunotherapies or combinations involving immunotherapies. One type of immunotherapy is an immune checkpoint inhibitor. Cells in the human body have proteins that regulate the immune system response to foreign invaders (e.g., cancer cells, microorganisms). However, cancer cells can coopt these “checkpoint” proteins and thwart the immune system’s ability to recognize and attack cancer cells. To help promote an immune response to cancer, researchers have developed immune checkpoint inhibitors that enable T-cells to recognize cancer cells as foreign and to prevent deactivation of an immune system response. To examine the challenges and opportunities to develop combination cancer therapies that include immune checkpoint inhibitors, the National Cancer Policy Forum held a workshop on July 16–17, 2018, in Washington, DC. This workshop convened stakeholders with a broad range of expertise, including cancer researchers, clinicians, patient advocates, and representatives from industry, academia, and government. This publication summarizes the presentations and discussions from the workshop"--Publisher's description

New Therapies and Immunological Findings in Melanoma and Other Skin Cancers

New Therapies and Immunological Findings in Melanoma and Other Skin Cancers Book
Author : Atsushi Otsuka,Reinhard Georg Dummer
Publisher : Frontiers Media SA
Release : 2019-01-15
ISBN : 2889457125
Language : En, Es, Fr & De

GET BOOK

Book Description :

New therapies are currently being developed in the field of skin cancer. In particular, advances in melanoma now represent the frontline of cancer immunotherapy, as immunological findings in the disease have led to the development of highly effective immune-checkpoint inhibitors. However, these immune-checkpoint inhibitors are only effective in a subset of patients, and may not work in other skin cancer types, thus highlighting the need for further innovation in the field of skin cancer treatment. The purpose of this Research Topic is therefore to provide an up-to-date overview of immune processes and new therapies for melanoma and other skin cancers in order to further stimulate the development of new and even more successful treatments.

Evidence based Advance and Management of Adverse Events of Immunotherapy for Cancer

Evidence based Advance and Management of Adverse Events of Immunotherapy for Cancer Book
Author : Yonggang Zhang,Xuelei Ma,Shuang Zhou
Publisher : Frontiers Media SA
Release : 2020-12-22
ISBN : 2889662470
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Evidence based Advance and Management of Adverse Events of Immunotherapy for Cancer book written by Yonggang Zhang,Xuelei Ma,Shuang Zhou, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.